Eli Lilly and Company (LLY)
| Market Cap | 221.62B |
| Revenue (ttm) | 26.73B |
| Net Income (ttm) | 6.07B |
| Shares Out | 907.30M |
| EPS (ttm) | 6.65 |
| PE Ratio | 34.84 |
| Forward PE | 26.25 |
| Dividend | $3.18 (1.37%) |
| Ex-Dividend Date | Aug 12, 2021 |
| Volume | 1,642,578 |
| Open | 232.77 |
| Previous Close | 232.18 |
| Day's Range | 231.34 - 235.47 |
| 52-Week Range | 127.04 - 275.87 |
| Beta | 0.25 |
| Analysts | Buy |
| Price Target | 266.88 (+15.2%) |
| Est. Earnings Date | Oct 26, 2021 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for me...
Financial Performance
In 2020, Eli Lilly's revenue was $24.54 billion, an increase of 9.95% compared to the previous year's $22.32 billion. Earnings were $6.19 billion, a decrease of -25.54%.
Financial StatementsAnalyst Forecast
According to 19 analysts, the average rating for Eli Lilly stock is "Buy." The 12-month stock price forecast is 266.88, which is an increase of 15.19% from the latest price.
News
Eli Lilly and Company Issues Voluntary Nationwide Recall of One Lot of GLUCAGON® Emergency Kit Due to Loss of Potency
INDIANAPOLIS, Sept. 24, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) is voluntarily recalling lot D239382D, Expiration April 2022, of Glucagon Emergency Kit for Low Blood Sugar (Glucagon for I...
Where to Invest $10,000 in a Bear Market
For now, both of these high-quality companies may be a bit overvalued, but that could change.
Lilly (LLY) to Supply COVID Cocktail Drug to EU Countries
Elli Lilly (LLY) is set to supply 220,000 doses of its COVID-19 antibody cocktail to European Union member nations, following approval.
Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount...
INDIANAPOLIS, Sept. 21, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the pricing terms of its previously announced cash tender offer for specified series of its outstanding deb...
Lilly announces procurement agreement with European Commission to supply bamlanivimab and etesevimab together for the...
INDIANAPOLIS, Sept. 21, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a Joint Procurement Agreement with the European Commission (EC) to supply up to 220,000 doses of bamlanivim...
Lilly Announces the Early Tender Results of Its Pending Cash Tender Offer for Up to $1.5 Billion Combined Aggregate P...
INDIANAPOLIS, Sept. 21, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the early tender results of its previously announced cash tender offer for specified series of its outstand...
Big Pharma Stocks Hit Hard by Drug Price Proposals
Drug stocks are in a tailspin, and you need to look no farther than Washington for the primary reason. A White House plan to cut the price of medications has led to a more than 10% drop in the Dow Jones...
Lilly (LLY) Gets FDA Nod for Expanded Use of COVID Cocktail
FDA revises Lilly's (LLY) EUA for COVID-19 antibody cocktail, bamlanivimab and etesevimab, for post-exposure prophylaxis for COVID-19.
AbCellera Stock Is Moving Higher After Expanded Use Nod For Lilly-Partnered COVID-19 Antibody
The FDA has expanded the Emergency Use Authorization (EUA) for bamlanivimab 700 mg and etesevimab 1400 mg administered together to include post-exposure prophylaxis in certain individuals to prevent SAR...
Emergency Use Authorization for Lilly's bamlanivimab and etesevimab administered together expanded to include post-ex...
INDIANAPOLIS, Sept. 16, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab 700 mg and etesevimab 1400 mg administered to...
Regeneron, Lilly Get New COVID Drug Deals From Government
Regeneron (REGN) is set to supply an additional 1.4 million doses of its antibody cocktail for COVID-19, REGEN-COV while Lilly (LLY) will supply 388,000 doses of its COVID-19 antibody medicine, etesevim...
Smart Investors Are Watching This Trend Right Now
It has to do with the coronavirus -- but it's not about vaccines.
After Regeneron, US Government Orders Additional COVID-19 Therapy From Eli Lilly
The U.S. government has announced to purchase additional doses of Eli Lilly And Co's (NYSE: LLY) for its neutralizing antibody therapies for COVID-19. Related Link: Distribution Resumes Of Eli Lilly COV...
Lilly to supply 388,000 doses of etesevimab to U.S. government for treatment of COVID-19
INDIANAPOLIS, Sept. 15, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced an additional purchase by the U.S. government for its neutralizing antibody therapies authorized for emerge...
Lilly to Participate in the 2021 Cantor Virtual Global Healthcare Conference
INDIANAPOLIS, Sept. 13, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021.
Lilly to Present New Data from Oncology Portfolio at ESMO Congress
INDIANAPOLIS, Sept. 13, 2021 /PRNewswire/ -- New data from various studies of Eli Lilly and Company's (NYSE: LLY) Verzenio® (abemaciclib), Retevmo® (selpercatinib) and CYRAMZA® (ramucirumab) will be pre...
Why Eli Lilly's COVID Antibody Therapy Is Making a Comeback
There's a one-word answer: delta.
Lilly's (LLY) Jardiance Gets Breakthrough Therapy Tag for HFpEF
The FDA bestows a Breakthrough Therapy status on Lilly's (LLY) Jardiance for heart failure with preserved ejection fraction (HFpEF).
Here's Why ProQR Stock Surged on Thursday
A new collaboration deal with Eli Lilly could be worth up to $1.3 billion.
Lilly Prices First Sustainability Bond to Advance Global ESG Strategy
INDIANAPOLIS, Sept. 9, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the pricing of its first sustainability bond to advance its global environmental, social and governance (ESG...
Empagliflozin receives Breakthrough Therapy Designation in U.S. for heart failure with preserved ejection fraction (H...
INGELHEIM, Germany & INDIANAPOLIS--(BUSINESS WIRE)--Empagliflozin receives Breakthrough Therapy Designation in U.S. for heart failure with preserved ejection fraction (HFpEF)
FDA grants Jardiance® Breakthrough Therapy designation for heart failure with preserved ejection fraction
RIDGEFIELD, Conn. and INDIANAPOLIS, Sept.
Eli Lilly Inks Another RNA Collab, This Time With ProQR
Eli Lilly And Co (NYSE: LLY) is doubling down on RNA research as it pens another pact with a quiet RNA editing player focused on neuroscience, ProQR Therapeutics N.V. (NASDAQ: PRQR).
Lilly Diabetes joins The Leona M. and Harry B.
INDIANAPOLIS, Sept. 7, 2021 /PRNewswire/ -- Lilly Diabetes will commit nearly $1 million over the next three years in a joint effort with The Leona M.
Lilly Announces Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt ...
INDIANAPOLIS, Sept. 7, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it has commenced a cash tender offer for up to $1.5 billion combined aggregate principal amount (the "T...